" class="no-js "lang="en-US"> Bruno Ultra Barcelos is appointed MD of Ethypharm UK
Tuesday, April 23, 2024

Bruno Ultra Barcelos is appointed Managing Director of Ethypharm UK

The Ethypharm Group, a European pharmaceutical company focused on the Central Nervous System and Hospital injectables,  appoints Bruno Ultra Barcelos as Managing Director of its UK subsidiary. Bruno Ultra Barcelos holds an Executive MBA from Kellogg-WHU. He has 30 years of experience in Europe with large international pharmaceutical groups, specialising in both specialities, biosimilars and generic medicines (Schering-Plough, Teva Pharmaceuticals, Novartis Group).

Bruno has held increasingly responsible commercial positions in both sales and marketing, up to General Management positions in Europe. He joins Ethypharm from Sandoz, where he was Country Head for Belgium and Luxembourg. Bruno Ultra Barcelos joins the Ethypharm Group as Managing Director of the Ethypharm UK subsidiary, Ethypharm’s first commercial affiliate, representing 30% of its turnover.

“I am proud to join Ethypharm and very excited about this new challenge. As Managing Director of Ethypharm UK I will continue to foster a growth mindset and focus the teams on the opportunities ahead. I look forward to leading the talented people in place to continue to develop and grow our business, with a focus on the service to our customers and on the safety and quality of our medicines,” says Bruno Ultra Barcelos.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more